Chronic wound care is a wound that persists after 4-6 weeks, and a complex wound is one that a health care professional is the one who needs to take care of it. The lack of progression and the complex nature of the wounds are due to multiple reasons and can be explained by the following factors1:
- patient-related factors (lack of assessment of comorbidities or factors contributing to the wound, and difficulties related to the patient’s behavior and cooperation);
- factors related to the wound (surface, volume, damage to the noble tissues, misdiagnosis of the etiology of the wound, and lack of diagnosis of infectious or ischemic complications of the wound);
- factors related to the skills and knowledge of health professionals (absence of standardized or appropriate care protocols);
- factors related to environmental or social difficulties in terms of resources available for the treatment of the wound.
The US Food and Drug Administration (FDA) has cleared the Omeza Collagen Matrix, a drug-device combination matrix for chronic wound care … The approval was granted through the FDA 510(k) premarket notification process. It is the first combination drug/device designed for chronic wound care … The wound care matrix is composed of hydrolyzed fish collagen infused with cod liver oil and other plant-derived oil and wax. After it is applied to a wound, the matrix is incorporated into the wound over time … read more
New research shows thermal imaging techniques can predict whether a wound needs extra management, offering an early alert system to improve chronic wound care … It is estimated that 1-2% of the population will experience a chronic wound during their lifetime in developed countries. In the U.S., chronic wounds affect about 6.5 million patients with more than $25 billion each year spent by the healthcare system on treating related complications … read more
New research shows thermal imaging techniques can predict whether a wound needs extra management, offering an early alert system to improve chronic wound care … It is estimated that 1-2% of the population will experience a chronic wound during their lifetime in developed countries – in the US, chronic wounds affect about 6.5 million patients with more than US$25 billion each year spent by the healthcare system on treating related complications … The Australian study shows textural analysis of thermal images of venous leg ulcers (VLUs) can detect whether a wound needs extra management as early as week two for clients receiving treatment at home … read more
Principle Investigators, Dr. Pons and Dr. Teichman, discuss a Pooled analysis of 434 wounds at 30 centers that supports the use of PuraPly AM to advance wounds out of the inflammatory phase. Discussions include presentations of real-world case reviews … Click HERE to view.
Morselized Umbilical Cord and Amniotic Membrane
MIAMI–(BUSINESS WIRE)–TissueTech Inc., the pioneer in the development and clinical application of regenerative amniotic tissue-based products, announced that it has been awarded patent 9,808,491 by the U.S. Patent Trademark Office. The patent applies to the use of a gel composition comprising morselized placental amniotic membrane and/or morselized umbilical cord. as a method for treating an ocular wound or repairing damaged ocular tissue.
“TissueTech has been the leader in the development and clinical application of amniotic membrane transplantation for the treatment of a variety of patient conditions in ophthalmology, chronic wound care, orthopedics and sports medicine,” said Amy Tseng, Chief Executive Officer of TissueTech. “We are excited that this patent represents our continued innovation and is another step forward in excelling our technological advances in the industry.”